BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ultragenyx Announces Completion of Phase 2 Study Enrollment for UX001 in Hereditary Inclusion Body Myopathy


10/30/2012 6:52:18 AM

NOVATO, Calif., Oct. 30, 2012 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced it has completed patient enrollment in a randomized, double-blind, placebo-controlled Phase 2 study of UX001 in patients with hereditary inclusion body myopathy (HIBM). The study's primary objective is to evaluate safety, dose, and improvements in sialylation biochemistry of muscle from pre-treatment to post-treatment biopsies (pharmacodynamic endpoint). Muscle strength, clinical function and patient-reported outcomes will also be evaluated, though the study is not powered for these endpoints. A total of 45 patients between 18 and 65 years of age, with a confirmed genetic mutation for HIBM, have been randomized to placebo versus two dose levels of active drug at four clinical sites in the US and Israel.

Read at GlobeNewswire

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES